Next Article in Journal
Tracing the Photoaddition of Pharmaceutical Psoralens to DNA
Next Article in Special Issue
Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells
Previous Article in Journal
Nanoporous Crystalline Composite Aerogels with Reduced Graphene Oxide
Previous Article in Special Issue
Antitumor, Immunomodulatory and Antiangiogenic Efficacy of Medicinal Mushroom Extract Mixtures in Advanced Colorectal Cancer Animal Model

Implementing Curcumin in Translational Oncology Research

Laboratory for Epigenomics, Ruđer Bošković Institute, Division of Molecular Medicine, 10000 Zagreb, Croatia
Institute for Clinical Medical Research and Education, University Hospital Centre Sisters of Charity, 10000 Zagreb, Croatia
Department of Clinical Oncology, School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
Author to whom correspondence should be addressed.
Academic Editors: Krešimir Pavelić and Sandra Sandra Kraljevic Pavelic
Molecules 2020, 25(22), 5240;
Received: 12 October 2020 / Revised: 29 October 2020 / Accepted: 4 November 2020 / Published: 10 November 2020
(This article belongs to the Special Issue Translational Approach to Antitumor Drugs)
Most data published on curcumin and curcumin-based formulations are very promising. In cancer research, the majority of data has been obtained in vitro. Less frequently, researchers used experimental animals. The results of several clinical studies are conclusive, and these studies have established a good foundation for further research focusing on implementing curcumin in clinical oncology. However, the issues regarding timely data reporting and lack of disclosure of the exact curcumin formulations used in these studies should not be neglected. This article is a snapshot of the current status of publicly available data on curcumin clinical trials and a detailed presentation of results obtained so far with some curcumin formulations. Phenomena related to the observed effects of curcumin shown in clinical trials are presented, and its modifying effect on gut microbiota and metabolic reprogramming is discussed. Based on available data, there is a strong indication that curcumin and its metabolites present molecules that do not necessarily need to be abundant in order to act locally and benefit systemically. Future clinical studies should be designed in a way that will take that fact into consideration. View Full-Text
Keywords: cancer therapy; clinical trials; microbiota; IL-17; nicotinamide N-methyltransferase; metabolic reprogramming; curcumin formulations cancer therapy; clinical trials; microbiota; IL-17; nicotinamide N-methyltransferase; metabolic reprogramming; curcumin formulations
Show Figures

Figure 1

MDPI and ACS Style

Trošelj, K.G.; Samaržija, I.; Tomljanović, M.; Kujundžić, R.N.; Đaković, N.; Mojzeš, A. Implementing Curcumin in Translational Oncology Research. Molecules 2020, 25, 5240.

AMA Style

Trošelj KG, Samaržija I, Tomljanović M, Kujundžić RN, Đaković N, Mojzeš A. Implementing Curcumin in Translational Oncology Research. Molecules. 2020; 25(22):5240.

Chicago/Turabian Style

Trošelj, Koraljka Gall, Ivana Samaržija, Marko Tomljanović, Renata Novak Kujundžić, Nikola Đaković, and Anamarija Mojzeš. 2020. "Implementing Curcumin in Translational Oncology Research" Molecules 25, no. 22: 5240.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop